Amneal Pharmaceuticals, Inc. Overview
Pro stress-test →Amneal Pharmaceuticals is a diversified global biopharmaceutical company that develops, manufactures, and distributes generic medicines, specialty branded pharmaceuticals, biosimilars, and injectable products. Operating through three segments (Affordable Medicines, Specialty, and AvKARE), Amneal serves the U.S. healthcare market and international regions, positioning itself as one of America's largest generic drug producers.
Strategic Profile
Pro stress-test →The company has demonstrated six consecutive years of growth with a strategic focus on complex product launches, biosimilar expansion, and GLP-1 manufacturing partnerships with Pfizer. Amneal is building competitive advantages through injectables leadership, a 280+ product generic portfolio, specialty brands targeting Parkinson's and endocrine disorders, and government contracting through AvKARE, while significantly improving operational margins and reducing debt costs.
Competitive Landscape
Pro stress-test →Amneal competes in the highly consolidated generic pharmaceutical market against major players including Teva, Hikma, Sandoz, Mallinckrodt, and specialty pharma peers like Bausch Health. Competitive advantages include complex generic/injectable capabilities, biosimilar platforms, and government contracting scale, though facing pricing pressure typical of generics and specialty brand competition from larger integrated majors like Eli Lilly and Bristol-Myers Squibb.
Industry Context
Amneal Pharmaceuticals, Inc. operates in Biopharmaceuticals / Specialty Generics.
Key facts
Founded: 2002 · Headquarters: Bridgewater, United States · Revenue: $3.0B · Market cap: $4.34B